Browsing ICR Divisions by author "James, Nicholas"
Now showing items 21-40 of 71
-
COmparing Urolift and Standard Transurethral resection of prostate Ahead of Radiotherapy in men with urinary symptoms secondary to prostate enlargement in Southwest London and North Cumbria (CO-STAR): a study protocol for a randomised feasibility study.
Wong, K; Kinsella, N; Seth, J; Nicol, D; Cahill, D; et al. (BMJ PUBLISHING GROUP, 2023-10-06)INTRODUCTION: Patients undergoing prostate radiotherapy with an enlarged prostate can have short-term and long-term urinary complications. Currently, transurethral resection of the prostate (TURP) is the mainstay surgical ... -
Correlation of Clinician- and Patient-Reported Outcomes in the BC2001 Trial.
Philipps, L; Porta, N; James, N; Huddart, R; Hafeez, S; et al. (ELSEVIER SCIENCE LONDON, 2023-05-01)AIMS: To evaluate whether there is sufficient correlation between patient-reported outcomes (PROs) and clinician-reported outcomes (CROs) in bladder cancer follow-up post-radiotherapy to streamline data collection and to ... -
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)
Andronis, L; Goranitis, I; Pirrie, S; Pope, A; Barton, D; et al. (2017-04-01) -
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Andronis, L; Goranitis, I; Pirrie, S; Pope, A; Barton, D; et al. (2017-04)Objective To evaluate the cost-effectiveness of adding zoledronic acid or strontium-89 to standard docetaxel chemotherapy for patients with castrate-refractory prostate cancer (CRPC).Patients and methods Data on resource ... -
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
Clarke, CS; Hunter, RM; Gabrio, A; Brawley, CD; Ingleby, FC; et al. (PUBLIC LIBRARY SCIENCE, 2022-01-01)Adding abiraterone acetate (AA) plus prednisolone (P) to standard of care (SOC) improves survival in newly diagnosed advanced prostate cancer (PC) patients starting hormone therapy. Our objective was to determine the value ... -
Development and validation of a follow-up methodology for a randomised controlled trial, utilising routine clinical data as an alternative to traditional designs: a pilot study to assess the feasibility of use for the BladderPath trial.
Mintz, HP; Dosanjh, A; Parsons, HM; Hughes, A; Jakeman, A; et al. (BMC, 2020-10-31)BACKGROUND: Bladder cancer outcomes have not changed significantly in 30 years; the BladderPath trial (Image Directed Redesign of Bladder Cancer Treatment Pathway, ISRCTN35296862) proposes to evaluate a modified pathway ... -
Differences in Quality of Life and Toxicity for Male and Female Patients following Chemo(radiotherapy) for Bladder Cancer.
Philipps, L; Porta, N; James, N; Huddart, R; Hafeez, S; et al. (ELSEVIER SCIENCE LONDON, 2023-02-01)AIMS: BC2001, a randomised trial of treatment for muscle-invasive bladder cancer, demonstrated no difference in health-related quality of life (HRQoL) or late toxicity between patients receiving radical radiotherapy with ... -
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
James, ND; Ingleby, FC; Clarke, NW; Amos, CL; Attard, G; et al. (OXFORD UNIV PRESS, 2022-07-01)BACKGROUND: STAMPEDE previously reported adding upfront docetaxel improved overall survival for prostate cancer patients starting long-term androgen deprivation therapy. We report long-term results for non-metastatic ... -
Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification.
Snell, KIE; Ward, DG; Gordon, NS; Goldsmith, JC; Sutton, AJ; et al. (Impact Journals, LLC, 2018-05-18)OBJECTIVES: To investigate whether elevated urinary HAI-1, EpCAM and EGFR are independent prognostic biomarkers within non-muscle-invasive bladder cancer (NMIBC) patients, and have utility for risk stratification to ... -
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.
James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; Mason, MD; et al. (AMER MEDICAL ASSOC, 2016-03-01)IMPORTANCE: The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. ... -
Gene expression profiling in bladder cancer identifies potential therapeutic targets.
Hussain, SA; Palmer, DH; Syn, W-K; Sacco, JJ; Greensmith, RMD; et al. (SPANDIDOS PUBL LTD, 2017-04-01)Despite advances in management, bladder cancer remains a major cause of cancer related complications. Characterisation of gene expression patterns in bladder cancer allows the identification of pathways involved in its ... -
Health-related quality of life around the time of diagnosis in patients with bladder cancer.
Yu, EY-W; Nekeman, D; Billingham, LJ; James, ND; Cheng, KK; et al. (WILEY, 2019-12-01)OBJECTIVES: To quantify the health-related quality of life (HRQoL) of patients with bladder cancer around the time of diagnosis and to test the hypotheses of a two-factor model for the HRQoL questionnaire QLQ-C30. METHODS: ... -
Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials.
Choudhury, A; Porta, N; Hall, E; Song, YP; Owen, R; et al. (ELSEVIER SCIENCE INC, 2021-02-01)BACKGROUND: Two radiotherapy fractionation schedules are used to treat locally advanced bladder cancer: 64 Gy in 32 fractions over 6·5 weeks and a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks. Long-term ... -
Integrated Care in Prostate Cancer (ICARE-P): Nonrandomized Controlled Feasibility Study of Online Holistic Needs Assessment, Linking the Patient and the Health Care Team.
Nanton, V; Appleton, R; Dale, J; Roscoe, J; Hamborg, T; et al. (JMIR PUBLICATIONS, INC, 2017-07-28)BACKGROUND: The potential of technology to aid integration of care delivery systems is being explored in a range of contexts across a variety of conditions in the United Kingdom. Prostate cancer is the most common cancer ... -
Making administrative healthcare systems clinical data the future of clinical trials: lessons from BladderPath
Mintz, HP; Dosanjh, ARS; Parsons, H; Sydes, M; Bryan, RT; et al. (BMJ, 2023-07-01) -
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
Gillessen, S; Bossi, A; Davis, ID; de Bono, J; Fizazi, K; et al. (ELSEVIER SCI LTD, 2023-05-01)BACKGROUND: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant ... -
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
Gillessen, S; Bossi, A; Davis, ID; de Bono, J; Fizazi, K; et al. (ELSEVIER, 2023-03-01)BACKGROUND: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of ... -
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Gillessen, S; Omlin, A; Attard, G; de Bono, JS; Efstathiou, E; et al. (ELSEVIER, 2015-08-01)The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) ... -
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Gillessen, S; Armstrong, A; Attard, G; Beer, TM; Beltran, H; et al. (ELSEVIER, 2022-07-01)BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. ... -
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bjartell, A; et al. (ELSEVIER, 2020-04-01)BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform ...